Just use toremifene already

AwhYeah

AwhYeah

Banned
This is my second PCT with toremifene citrate; 120/90/60/30.

Took my first dose Sunday night after my mentabolan/stano cycle(ment is a 19-nor; turned my balls to raisins in 8 weeks).

It's now Wednesday morning (obviously) and I have had morning wood and random woodies throughout the day since I started dosing Torem. Ment actually crashed my libido, so this is nice.

My lifts have increased a rep on deads, bench, and dip (squats tomorrow). I feel awesome; outstanding energy and wellbeing.

My fellas down-under are rejoicing. Righty is full and happy, lefty was the smallest and has come back to about 70-80%, keep in mind it's haven't even been 3 full days.

Torem is in conjunction with DAA 3g and EndoSurge 6 caps.

Dare I say I'm excited for blood work?

Invalid Link Removed
 
Intriguing!! That was actually my original plan but torem being a derivative of nolva, I figured it had progesterone activity too.
 
da_tank55 said:
Intriguing!! That was actually my original plan but torem being a derivative of nolva, I figured it had progesterone activity too.
Click to expand...

What I could find right now:

I was wondering if anyone used toremifene will using tren ( with test of course lol). Nolva will increase PgR in breast tissue so is a no no while using tren( it will increase receptors and give trens metabolites more to bind to) Anyways toremifene does not see to have the same effect on PgR as nolva. Here is a study that shows it has minimal effect on PgR.

Cancer. 1990 Dec 1;66(11):2264-9. Related Articles, Links

Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.

Valavaara R, Tuominen J, Johansson R.

Department of Radiotherapy, University of Turku, Finland.

The predictive value of estrogen receptor (ER) concentrations was evaluated in a group of 113 postmenopausal patients with estrogen-receptor-positive (ER greater than 7 fmol/mg protein) advanced breast cancer. In 103 patients, tumors were also sampled for progesterone receptor (PgR) determination. All patients were treated with toremifene, a novel antiestrogen, 60 mg daily. The median ER in 51 responders was 78 fmol/mg protein, and in 62 nonresponders, 51 fmol/mg protein; the median PgR levels were 40 and 37 fmol/mg protein, respectively. The response rate in patients with ER less than 50 fmol/mg protein was 38%, and 51% in the group with ER greater than 50 fmol/mg protein (not significant [NS]). The response rate in patients with PgR less than 10 fmol/mg protein was 42%, and in patients with greater than 10 fmol/mg protein, 44%.The duration of response in patients with ER greater than 50 fmol/mg protein was significantly longer than with lower ER levels (P = 0.002). PgR was not associated with the duration of response. In Cox's multiple regression analysis, ER was an independent prognostic factor (P = 0.005) for response duration. Thus, the ER concentration of tumor tissue predicts the duration of response but not the response rate to toremifene in patients with advanced breast cancer. The PgR status does not predict the response rate or the duration of response.............



The study is from Finland, where the drug was conceived.
 
You must log in or register to reply here.
Back
Top